Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

Change From Baseline in Systolic Blood Pressure (SBP)

Time frame: Baseline to 3rd visit (4-10 months)

Change From Baseline in Diastolic Blood Pressure (DBP)

Time frame: Baseline to 3rd visit (4-10 months)

Change From Baseline in SCORE (10 Year Risk for Fatal Cardiovascular Event)

A 10 year risk of fatal cardiovascular disease (CVD) in populations at high risk. Minimum 0 percent risk to Maximum 47 percent risk.

Time frame: Baseline to 3rd visit (4-10 months)

Change From Baseline in Framingham CVD Risk Assessment Score

10-year risk for hard coronary heart disease (CHD) outcomes (Myocardial Infarction and coronary death), according to Framingham Heart Study, measured in percent. Low risk (10 or less CHD risk at 10 years), intermediate risk (10-20), high risk (20 or more).

Time frame: Baseline to 3rd visit (4-10 months)

Change From Baseline in Framingham Stroke Risk Assessment Score

The risk assessment tool using data from the Framingham Heart Study to estimate 10-year risk for stroke, measured in percent. Low risk (10 or less stroke risk at 10 years), intermediate risk (10-20), high risk (20 or more).

Time frame: Baseline to 3rd visit (4-10 months)

Change From Baseline in Risk Assessment According to ESH/ESC Guidelines

ESH is the European society of hypertension, and ESC is the European society of cardiology.

Time frame: Baseline to 3rd visit (4-10 months)